RudaCure, une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels, drew significatif attention at a major international rheumatology conference.
Selon RudaCure Inc. (PDG Yongho Kim), l'entreprise presented efficacité préclinique results of its arthrose treatment candidate under development at the American College of Rheumatology (ACR) Annual Meeting, held in San Diego, USA from the 10th to the 15th, receiving considerable interest from attendees.
The compound discovered by RudaCure features a mechanism that selectively inhibits TRPV1 activation. In prior studies, it demonstrated TRPV1 inhibitory effects and reduced pain in douleur chronique animal models. Notamment, unlike existing TRPV1 antagonists, it did not cause abnormal hyperthermia.
In addition to the présentation de poster, RudaCure was also invited to the BCRC (Basic & Clinical Research Conference) session—one of the key programs at ACR 2023—where de l'entreprise cumulative research findings were presented directly to the audience.
RudaCure le PDG Yongho Kim a déclaré : "By moving away from traditional développement de médicaments methods with low success rates in the pain field and leveraging computational science, we were able to rapidly identify composé principals," adding, "En particulier, having a diverse range of pain models allowed us to quickly and accurately address développement de médicaments and side effect challenges, which is a key advantage."
He further a noté : "Sur la base de these research results, we plan to expand the indications for divers pain conditions," and "We are also pursuing the development of a drug that can suppress pain for several months with a single administration through formulation research."
Source: Pharmnews (http://www.pharmnews.com)
http://www.biospectator.com/view/news_view.php?varAtcId=20336